NCT02653118Active, not recruitingPhase 3
A scientific study on a vaccine against HPV infection (human papilloma virus) (a vaccine for the prevention of cervical cancer and genital warts)
A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Aug 2026
Brief summary (registry, in English)
To assess the long-term effectiveness of the 9vHPV vaccine by monitoring the combined incidence of Cervical Intraepithelial Neoplasia (CIN) 2, CIN 3, Adenocarcinoma In Situ (AIS) and cervical cancer related to HPV 16, 18, 31, 33, 45, 52, and 58 in women from Protocol V503-001 in the Nordic region vaccinated with the 9vHPV vaccine
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 2220 (estimated)
- First submitted
- 17 Apr 2024
- Start date
- 14 Mar 2008
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Cervical cancer, Childhood cancers
- EU CT number
- 2023-508683-30-00
- EudraCT number
- 2013-003549-40
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 2220
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- There are no exclusion criteria
Who the study is looking for
- Randomized into the V503-001 (NCT00543543) study from a Denmark, Norway, or Sweden site and participated in the study by receiving either the selected dose formulation of the 9vHPV vaccine or GARDASIL
- Agrees to allow passive follow-up, analysis of biopsy specimens, future contact from the National Registry Study Centers, and serum collection
Age in the registry: 18 years to 64 years · Sex: Female · Accepts healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Danish Cancer Society Research Center Coordinator of this site? Confirm its status | Copenhagen Oe | Denmark | Not yet recruiting |
| Sanos A/S Coordinator of this site? Confirm its status | Gandrup | Denmark | Not yet recruiting |
| Sanos A/S Coordinator of this site? Confirm its status | Herlev | Denmark | Not yet recruiting |
| Odense University Hospital Coordinator of this site? Confirm its status | Odense C | Denmark | Not yet recruiting |
| Sanos A/S Coordinator of this site? Confirm its status | Vejle | Denmark | Not yet recruiting |
| Cancer Registry Of Norway Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
| Karolinska University Hospital Coordinator of this site? Confirm its status | Huddinge | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.